Registration is now open for the second Hybrid Public Workshop on Artificial Intelligence in Drug and Biological Product Development, hosted by the U.S. Food and Drug Administration in collaboration with the Clinical Trials Transformation Initiative. The event will take place on October 7, 2025, in person at The National Press Club in Washington, DC, and online via Zoom.

Join experts from across sectors for a forward-looking discussion on how artificial intelligence (AI) is transforming drug and biological product development. Building on momentum from the first workshop in 2024, this year’s event will highlight real-world breakthroughs and explore how AI is advancing the safety, efficacy, and quality of drugs and biological products.

Speakers will address best practices, cross-disciplinary collaboration, and practical strategies to improve data quality, reduce bias, and increase transparency in AI models. Attendees will gain insights into responsible applications of AI in clinical research and to support regulatory decisions, along with opportunities to support innovation across the field.

The workshop will run from 9:00 a.m. to 5:00 p.m. Eastern Daylight Time. Attendance is free and open to the public.

Register now to be part of this important conversation on the future of AI in medical product development.